Abstract
Introduction
 A Markov model with yearly cycles consisting of the three health states 'Blind', 'Visual Impaired' and 'Death' was developed in Excel 2010 in order to simulate and to compare the costs and effects of next generation AVDs versus best supportive care (BSC).  As the development of these next generation AVDs is currently in a pre-clinical stage, the actual treatment effect is not yet predictable and hence there is a high uncertainty of treatment outcomes; therefore five different AVD responder rate scenarios (proportion of patients that obtain a vision improvement from 'Blind' to 'Visual Impaired': 25%, 50%, 75%, 100% and 62.5% as average base case) were applied in order to simulate the transition from the health states 'Blind' to 'Visual Impaired'.  For the survival analyses a starting age of 51 years (SD 5.3 years) was simulated as this is the mean age for the onset of bilateral blindness in RP [6] .  For the cost estimates a German healthcare payer perspective was applied. Yearly healthcare costs for the health states 'Blind' and 'Visual Impaired' were determined on the basis of published literature [7] ; it was assumed that these costs already include all relevant costs for the BSC strategy.  As the costs for the next generation AVDs are not yet determined (released) different costing scenarios were analyzed (using the cost of the first generation AVDs as estimation basis): the first year cost were set at € 55,000, €70,000, €85,000 (mean base case), €100,000 and at €115,000 whereas the annual follow-up costs were kept constant at €1,500.  The effect (utility) estimates are based on published health related quality-of-life estimates. According to a recent NORC report [8] the average health utility is 0.61 for the health state 'Blind' (based on 6 publications), and 0.77 for 'Visual Impaired' (based on 8 publications); a health utility of zero was applied for the state 'Death'.  Costs and effects were discounted by 3% per annum according to German health economic recommendations (Institute for Quality and Efficiency in Healthcare -IQWiG -2009 [9] ).  Probabilistic sensitivity analyses and deterministic sensitivity analyses were performed in order to investigate the robustness of results.  The results are provided as incremental cost effectiveness ratio (ICER) that is expressed as the cost per quality-adjusted life year (QALY) gained comparing next generation AVDs versus BSC from a German healthcare payer perspective. Objectives: The next generation of artificial vision devices (AVDs), currently developed in pre-clinical settings, has the potential to improve the vision of blind patients with retinitis pigmentosa (RP) in a manner that they will be categorized as visual impaired but no longer as blind. This unprecedented vision improvement will result in a mentionable quality of life gain which poses the question at which costs the next generation AVDs are to be regarded as cost-effective from a German healthcare payer perspective.
Methods:
In order to answer this research question a Markov model, with the health states blind, visual impaired and death, was developed to simulate and to compare the costs and effects of next generation AVDs versus best supportive care over a lifetime horizon. Healthcare costs and health utilities for the Markov health states were determined on the basis of published literature. For next generation AVDs, which are currently tested in clinical trials, various possible effect and pricing scenarios have been simulated.
Results:
Applying the base case settings resulted in incremental costs of €107,925, in 2.03 incremental qualityadjusted life years (QALYs) and in a cost-effectiveness ratio of €53,165 per QALY gained. Probabilistic and deterministic sensitivity analyses as well as scenario analyses for the effect size and the AVD costs were performed in order to investigate the robustness of results. In these analyses a strong variation of the costeffectiveness results was obtained ranging from €23,512 (best case) to €176,958 (worst case) per QALY gained.
Conclusions:
The innovative nature, the high unmet medical need and the expected unprecedented efficacy of next generation AVDs will highly likely lead to the case that even relatively high incremental cost-effectiveness ratios, that have been obtained when simulating various effect and pricing scenarios, will be regarded as acceptable from a German healthcare payer perspective.
 After almost half a century of research activities artificial vision systems are moving in the clinical practice. These devices are designed to provide prosthetic vision to the blind by stimulating localized neural populations in one of the retinotopically organized structures of the visual pathway -typically the retina or visual cortex [1] .  According to the World Health Organization (WHO) blindness affects almost 45 million people worldwide (≈300,000 in Germany [2] ) and its prevalence constantly increases along with population aging [3] .  Retinitis pigmentosa (RP) accounts for ≈1 million patients worldwide [4] and for ≈20,000 patients in Germany [5] . In RP, photoreceptor degeneration leads to a progressive reduction of the visual field often declining to legal blindness; in these patients prosthetic vision is so far the only effective treatment strategy [4] .  The current generation of these artificial vision devices (AVDs) provides a level of prosthetic vision that allows RP patients to perceive light, recognize shapes and objects and even read large font print, which is already a substantial progress for the patients; however the visual acuity remains still in a region that is defined as legal blindness (best result 20/1260; legal blindness <20/200) [4] .  The next generation of AVDs, which is currently developed in pre-clinical settings, has the future potential to improve the vision of blind patients in a manner that they will be categorized as visual impaired but no more as blind (visual acuity >20/200) [4] .  This unprecedented vision improvement will result in a mentionable quality of life gain which poses the question at which effect size and at which cost next generation AVDs will be regarded as cost-effective when compared to the current practice (best supportive care) for treating blind patients with RP from a German healthcare payer perspective. 
Material and Methods

Discussion / Interpretation of Results
 In Germany there is no official WTP threshold per QALY gained in order to guide reimbursement decisions. However, systematic comparisons of the CE outcomes of a new intervention to CE outcomes of already reimbursed intervention(s), which are applied in the same disease area, are usually performed [9] . Such systematic comparisons are usually based on the efficacy frontier approach proposed by the IQWiG [10] .  For RP there is so far no German CE study published but there are studies published for age-related macular degeneration (ARMD), hence there are at least studies available that are related to the field of visual impairment/blindness.  Neubauer et al. investigated the cost-effectiveness of ranibizumab compared to BSC [placebo; sham injection] (in ARMD from a German healthcare payer perspective), which resulted in costs per QALY gained ranging from €13,505 (4 injections per year) to €87,862 (12 injections per year -as applied in the underlying phase III trials) [11] .  Hence it is currently not clearly predictable which WTP thresholds German authorities might apply for AVDs in RP. However considering these CE ratios for ARMD therapies and considering the high unmet medical need in blind RP patients (there is currently no effective therapy) it is likely that a cost-per QALY gained threshold of up to €80,000 will be considered as acceptable, as it is the case for ranibizumab in ARMD.  Irrespective of the discussions around the WTP threshold it needs to be considered that a reimbursement decision of AVDs, especially in the German setting, will not be limited to the outcomes of a CE assessment. Other, even more important decision criteria, such as the innovative nature of the AVD technology, the absence of effective therapy methods in RP (high unmet medical need) as well as the unprecedented therapy benefit (making the blind see again) will be taken into account in order to decide on the value and subsequently on the reimbursement of next generation AVDs.  Above it can be seen that 28% of the scenarios (7 of 25) are below a WTP threshold (per QALY gained) of €40,000; that 60% of the scenarios (15 of 25) are below a WTP threshold of €60,000 and that 76% of the scenarios (19/25) are below a WTP threshold of €80,000.  Additionally three scenarios (best case, base case and worst case) were selected in order to investigate the probability that AVDs (compared to BSC in RP) are a cost-effective intervention in case of assuming different WTP thresholds (Figure 4 ). Scenario definition (labels): The percentage defines the responder rate and the Euro value defines the first year AVD costs in thousands (e.g. 25%;€100 means AVD response rate of 25% and the first year AVD costs of €100,000)
Results
Limitations
 Early health economic evaluations differ from late-stage evaluations (e.g. those used at the time of reimbursement submission or as basis for health technology assessments) in that they are much more flexible and are designed to explore uncertainty. This means they typically operate on a less robust evidential basis than late-stage evaluations.  Also this early health economic evaluation has to handle with three main uncertainty factors: the effect size of next generation AVDs, the costs of next generation AVDs and the WTP threshold that might be applied in RP patients, which reflect the main limitations of the presented assessment.
 Comparing next generation AVDs versus BSC, while applying the base case settings, resulted in mean incremental costs of €107,925, in 2.03 mean incremental QALYs and in an ICER of €53,165 per QALY gained.  The result deviation (based on the probabilistic sensitivity analyses) is visualized (for the base case setting) in form of an ICER plane (Figure 1 -on the left).  The influence of single input parameters on the cost-effectiveness (CE) analyses results was investigated by applying oneway sensitivity analyses on all relevant input parameters (Figure 2 -on the left).  According to the Tornado diagram the variation of the response rate showed the strongest impact on the CE analyses results followed by the variation of the age at therapy start and variation of the observation time horizon.  The outcomes of the scenario analyses, on the AVD responder rate (RR) and on the first year AVD costs, are presented in Figure 3 , in relation to different willingness to pay (WTP) thresholds. In these analyses a strong variation of the costeffectiveness results was obtained ranging from €23,512 (best case; RR 100%; AVD first year costs €55,000) to €176,958 (worst case, RR 25%; €115,000) per QALY gained by AVD therapy. 
